Apimeds Pharmaceuticals US, Inc.

NYSE:APUS

Pharmaceutical Preparations·MATAWAN, NJ

Financials

5 shown

Type	Period	Ended	Filed
10-Q	Q3 2025	9/30/25	11/12/25	→
10-Q	Q2 2025	6/30/25	8/19/25	→
10-Q	Q1 2025	3/31/25	5/20/25	→
10-K/A	FY 2024	12/31/24	5/2/25	→
10-K	FY 2024	12/31/24	4/15/25	→

News (8-K)

12 shown

Filed	Type	Description
2/17/26	Acquisition	AMENDMENT NO. 2 TO FORM 8-K	→
1/2/26	Exec Change	Departure or Appointment of Directors or Certain Officers	→
12/10/25	Exec Change	Departure or Appointment of Directors or Certain Officers	→
12/10/25	Agreement	AMENDMENT NO. 1 TO FORM 8-K	→
12/2/25	Acquisition	Entry into a Material Definitive Agreement	→
11/18/25	Exec Change	Departure or Appointment of Directors or Certain Officers	→
↓

Prospectuses & Registrations

11 shown

Filed	Form	Description
5/23/25	S-8	REGISTRATION STATEMENT	→
5/9/25	424B4	424B4	→
2/10/25	FWP	FREE WRITING PROSPECTUS	→
2/10/25	S-1/A	REGISTRATION STATEMENT	→
2/6/25	S-1/A	REGISTRATION STATEMENT	→
1/29/25	S-1/A	REGISTRATION STATEMENT	→
↓

Filing History(102 filings)

TypeDateAccessionPeriodSize

DEFM14C

Feb 27, 2026

0001213900-26-020883INFORMATION STATEMENT

—

12.7 MB

425

Feb 17, 2026

0001213900-26-017331AMENDMENT NO. 2 TO FORM 8-K

—

445.4 KB

8-K/A

Feb 17, 2026

0001213900-26-017323AMENDMENT NO. 2 TO FORM 8-K

Dec 1, 2025

677.5 KB

SCHEDULE 13G

Feb 11, 2026

0001493152-26-006136

—

11.5 KB

SCHEDULE 13D/A

Jan 26, 2026

0001213900-26-007438

—

18.6 KB

PREM14C

Jan 16, 2026

0001213900-26-005174INFORMATION STATEMENT

Jan 16, 2026

12.5 MB

8-K

Jan 2, 2026

0001213900-26-000464CURRENT REPORT

Dec 30, 2025

188.4 KB

8-K

Dec 10, 2025

0001213900-25-119894CURRENT REPORT

Dec 5, 2025

183.8 KB

8-K/A

Dec 10, 2025

0001213900-25-119893AMENDMENT NO. 1 TO FORM 8-K

Dec 1, 2025

799.9 KB

425

Dec 2, 2025

0001213900-25-117176CURRENT REPORT

—

1.6 MB

8-K

Dec 2, 2025

0001213900-25-117173CURRENT REPORT

Dec 1, 2025

2.1 MB

4/A

Nov 21, 2025

0002057997-25-000002PRIMARY DOCUMENT

May 12, 2024

5.5 KB

8-K

Nov 18, 2025

0001213900-25-112184CURRENT REPORT

Nov 13, 2025

199.0 KB

Nov 13, 2025

0002040378-25-000004PRIMARY DOCUMENT

Nov 11, 2025

5.8 KB

Nov 13, 2025

0002041300-25-000003PRIMARY DOCUMENT

Nov 11, 2025

5.7 KB

Nov 13, 2025

0002041972-25-000004PRIMARY DOCUMENT

Nov 11, 2025

5.7 KB

Nov 13, 2025

0001573840-25-000003PRIMARY DOCUMENT

Nov 11, 2025

5.7 KB

Nov 13, 2025

0001679971-25-000008PRIMARY DOCUMENT

Nov 11, 2025

5.9 KB

10-Q

Nov 12, 2025

0001213900-25-109280QUARTERLY REPORT

Sep 30, 2025

4.0 MB

Oct 24, 2025

0001679971-25-000007PRIMARY DOCUMENT

Oct 15, 2025

8.9 KB

Oct 21, 2025

0001573840-25-000002PRIMARY DOCUMENT

Oct 15, 2025

5.7 KB

Oct 17, 2025

0002041972-25-000003PRIMARY DOCUMENT

Oct 15, 2025

9.1 KB

Oct 17, 2025

0002040378-25-000003PRIMARY DOCUMENT

Oct 15, 2025

9.2 KB

Oct 17, 2025

0002040022-25-000002PRIMARY DOCUMENT

Oct 15, 2025

5.8 KB

Oct 17, 2025

0002041300-25-000002PRIMARY DOCUMENT

Oct 15, 2025

5.7 KB

25 filings shown

Apimeds Pharmaceuticals US, Inc.

Financials

News (8-K)

Prospectuses & Registrations

Filing History(102 filings)

Proxies

Ownership

Other Filings

Filed	Form	Description
2/27/26	DEFM14C	INFORMATION STATEMENT	→
1/16/26	PREM14C	INFORMATION STATEMENT	→

Filed	Form	Description
11/21/25	4/A	PRIMARY DOCUMENT	→
11/13/25	4	PRIMARY DOCUMENT	→
11/13/25	4	PRIMARY DOCUMENT	→
11/13/25	4	PRIMARY DOCUMENT	→
11/13/25	4	PRIMARY DOCUMENT	→
11/13/25	4	PRIMARY DOCUMENT	→
↓

Filed	Form	Description
2/17/26	425	AMENDMENT NO. 2 TO FORM 8-K	→
2/11/26	SCHEDULE 13G	SCHEDULE 13G	→
1/26/26	SCHEDULE 13D/A	SCHEDULE 13D/A	→
12/2/25	425	425	→
5/19/25	SCHEDULE 13D	SCHEDULE 13D	→
5/5/25	EFFECT	EFFECT	→
↓